Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 1.3B$US for a 2030 drug

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston Aug 15, 2023 9:48am

259 Views

Post# 35588739

1.3B$US for a 2030 drug

1.3B$US for a drug that will only reach commercialization in 2030 (in 7y) only. This deal is to fasten its development. Obesity drugs are a hot topic these days.

https://www.reuters.com/markets/deals/novo-nordisk-acquire-obesity-drug-developer-inversago-2023-08-10/

Our treatment will be worth way more considering the fact that we're closer than that to commercialization (2026). The fact that our data will also be 50% into a Ph. 2 will give us more value as the doubt is removed.

So the waiting is worth it though in our case, that should be a jv for the moment, not a takeover, unless otherwise.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments